Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 29Esophageal Neoplasms 18Squamous Cell Carcinoma of Head and Neck 15Carcinoma, Non-Small-Cell Lung 14Nasopharyngeal Carcinoma 12Uterine Cervical Neoplasms 11Head and Neck Neoplasms 11Pancreatic Neoplasms 8Oropharyngeal Neoplasms 8Lung Neoplasms 6Glioblastoma 6Carcinoma, Squamous Cell 5Urinary Bladder Neoplasms 4Stomach Neoplasms 4Mouth Neoplasms 4Hypopharyngeal Neoplasms 4Esophageal Squamous Cell Carcinoma 4Colorectal Neoplasms 4Adenocarcinoma 4Radiation Injuries 3Pathologic Complete Response 3Carcinoma 3Breast Neoplasms 3Thymoma 2Resectable Esophageal Cancer 2Neoplasms 2Nasopharyngeal Neoplasms 2NSCLC 2Lymphoma 2Lymphatic Metastasis 2

Interventions

camrelizumab 4Oxaliplatin 3apatinib 2S 1 (combination) 2Capecitabine 2XELOX 1Taxes 1Surgical Procedures, Operative 1Nivolumab 1Laparoscopy 1Hyperthermic Intraperitoneal Chemotherapy 1Gastrectomy 1Conversion to Open Surgery 1Chemoradiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Locally Advanced Gastric Cancer × Chemoradiotherapy × Clear all
NCT05528367 2022-09-06

Tirelizumab in Combination With Chemoradiation in Patients With Unresectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Zhejiang Cancer Hospital

Phase 2 Unknown
33 enrolled
Gastrointestinal

Locally Advanced Gastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡